CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) AI Stock Summary

Snapshot

This is a pre-revenue biotechnology company burning cash rapidly. With only $6K in revenue for FY 2025 against a $6M net loss, the business relies entirely on external capital. The company holds $7.2M in cash but burns roughly $5.9M annually, leaving a tight cash runway of about 7.4 months. Shareholders face significant dilution pressure, with the share count up 61% year-over-year and a pending proposal to increase authorized shares four-fold while approving warrant exercises that would dilute existing holders by over 100%.

What's Happening Right Now

• Thu 6th Aug '26 · Patent: The company received a Notice of Allowance for a new U.S. patent covering exosome-based immunotherapy for Type 1 Diabetes.
• Fri 17th Jul '26 · Governance: A proxy statement seeks approval to increase authorized shares four-fold and exercise warrants that would dilute existing shareholders by over 100%.
• Tue 30th Jun '26 · Financing: The company entered agreements for the immediate exercise of warrants expected to generate $4.5 million in gross proceeds.
• Mon 22nd Jun '26 · Clinical: The FDA cleared an expansion of the ADAPT trial evaluating CELZ-201 for chronic lower back pain.

Ownership

Institutions hold 1.9% of shares, while insiders hold 0.0%.

Bottom Line

This stock is in a precarious financial position due to a tight cash runway. With less than eight months of cash remaining at current burn rates, the company is actively seeking to raise capital through warrant exercises that would dilute existing shareholders by over 100%. While clinical progress and new patents are promising, the immediate liquidity risk and aggressive dilution are the defining risks right now.